Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 7,287 | 907 | 6,227 |
| Samples | 995 | 199 | 768 |
| Peptides | 789 | 132 | 675 |
Function
HDAC9 · Histone deacetylase 9
Histones play a critical role in transcriptional regulation, cell cycle progression, and developmental events. Histone acetylation/deacetylation alters chromosome structure and affects transcription factor access to DNA. The protein encoded by this gene has sequence homology to members of the histone deacetylase family. This gene is orthologous to the Xenopus and mouse MITR genes. The MITR protein lacks the histone deacetylase catalytic domain. It represses MEF2 activity through recruitment of multicomponent corepressor complexes that include CtBP and HDACs. This encoded protein may play a role in hematopoiesis. Multiple alternatively spliced transcripts have been described for this gene but the full-length nature of some of them has not been determined. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
12 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000441542 | Q9UKV0-7 | 976 | 652 |
| ENST00000406451 | Q9UKV0-5 | 975 | 651 |
| ENST00000401921 | Q9UKV0-6 | 939 | 628 |
| ENST00000432645 | Q9UKV0 | 933 | 620 |
| ENST00000405010 | Q9UKV0-3 | 509 | 337 |
| ENST00000406072 | B5MCF1* | 490 | 329 |
| ENST00000417496 | Q9UKV0-8 | 489 | 328 |
| ENST00000456174 | Q9UKV0-10 | 484 | 317 |
| ENST00000622668 | B7Z3P7* | 474 | 315 |
| ENST00000428307 | Q9UKV0-9 | 472 | 313 |
| ENST00000524023 | Q9UKV0-11 | 444 | 291 |
| ENST00000686413 | Q9UKV0-7 | 102 | 99 |
Gene Properties
Recurrent Mutations
All 652 amino-acid changes on canonical ENST00000441542 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in HDAC9 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in HDAC9 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 5/26 19% | 0/0 0% |
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Melanoma | 21/210 10% | 176/1899 9% |
| Non-Small Cell Lung Carcinoma | 53/304 17% | 61/1390 4% |
| Endometrial Carcinoma | 6/42 14% | 25/612 4% |
| Squamous Cell Lung Carcinoma | 10/57 18% | 30/810 4% |
| Other Solid Cancers | 8/94 9% | 58/1515 4% |
| Colorectal Carcinoma | 20/143 14% | 97/3239 3% |
| Neuroendocrine Tumour | 15/154 10% | 8/577 1% |
| Gastric Carcinoma | 2/74 3% | 49/1809 3% |
| Ovarian Carcinoma | 8/109 7% | 18/998 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Hepatocellular Carcinoma | 6/46 13% | 40/2210 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Cervical Carcinoma | 3/35 9% | 6/422 1% |
| Mesothelioma | 3/62 5% | 1/165 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 12/752 2% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Biliary Tract Carcinoma | 0/54 0% | 15/950 2% |
| Pancreatic Carcinoma | 1/89 1% | 21/1611 1% |
| Head and Neck Carcinoma | 3/85 4% | 18/1574 1% |
| Esophageal Carcinoma | 0/23 0% | 10/769 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 28/2550 1% |
| Bladder Carcinoma | 0/58 0% | 10/956 1% |
| Ewings Sarcoma | 2/63 3% | 1/262 0% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Non-Cancerous | 1/104 1% | 7/830 1% |
| Glioma | 3/52 6% | 14/2127 1% |
| Breast Carcinoma | 5/144 3% | 21/3264 1% |
Mutation Distribution
Where HDAC9 is mutated · all tissues, split by cell line vs tissue
How many mutations in HDAC9 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 7,287 mutations in HDAC9
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|